Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22462856 | 1.00 | NR1H2 (0.53) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL29616656 | 1.00 | NR1H2 (0.53) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL31434070 | 1.00 | NR1H2 (0.53) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL34461164 | 1.00 | NR1H2 (0.53) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL22462855 | 1.00 | NR1H2 (0.53) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL25205542 | 0.90 | HPGD (0.48) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL18309953 | 0.90 | HPGD (0.48) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL14971268 | 0.90 | NR1H2 (0.53) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL15076438 | 0.89 | NR1H2 (0.46) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL15076681 | 0.89 | HPGD (0.47) | NR1H2HPGDMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741383-A1 | COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025011480-A1 | COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG | 泰励生物科技（上海）有限公司 | 2025-01-16 | — | — | WO | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| CN-112457296-B | Pyrimidine compound and preparation method thereof | 武汉人福创新药物研发中心有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20220204479-A1 | PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2022-06-30 | — | — | US | disclosed |
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-09-09 | — | — | US | disclosed |
| CN-112867720-A | Novel heterocyclic compounds as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021043260-A1 | PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | 湖北生物医药产业技术研究院有限公司 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043260-A1 | PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | 湖北生物医药产业技术研究院有限公司 | 2021-03-11 | — | — | WO | disclosed |
| CN-112457296-A | Pyrimidine compound and preparation method thereof | 湖北生物医药产业技术研究院有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112469724-A | Novel heterocyclic compounds as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2020023393-A1 | KINASE ANTAGONISTS AND METHODS FOR MAKING AND USING THEM | BIOBLOCKS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | NR1H2 352/4885HPGD 1396/4885MAPT 4648/4885 |
| US-20220204479-A1 | PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | TYMP, DPYD, TYMS | NR1H2 2642/4885HPGD 1444/4885MAPT 545/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | NR1H2 137/4885HPGD 2377/4885MAPT 4861/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | NR1H2 209/4885HPGD 1055/4885MAPT 4669/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | NR1H2 209/4885HPGD 1055/4885MAPT 4669/4885 |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, MGLL, LPL | NR1H2 203/4885HPGD 1090/4885MAPT 4642/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | NR1H2 209/4885HPGD 1055/4885MAPT 4669/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | NR1H2 1253/4885HPGD 3940/4885MAPT 4794/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | NR1H2 209/4885HPGD 1055/4885MAPT 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.